Decades of research have identified genetic factors and biochemical pathways involved in
neurodegenerative diseases (NDDs). We present evidence for the following eight hallmarks …

Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …

Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …

Remyelination, the myelin regenerative response that follows demyelination, restores
saltatory conduction and function and sustains axon health. Its declining efficiency with …

Microglia are implicated in all stages of multiple sclerosis (MS). Microglia alterations are
detected by positron emission tomography in people living with MS prior to the formation of …

Background and Objectives Neurodegeneration and astrocytic activation are pathologic
hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum …

Multiple sclerosis (MS) is an autoimmune disease characterized by demyelination of the
central nervous system (CNS). Autologous hematopoietic cell transplantation (HCT) shows …

Many challenges exist in the precise diagnosis and clinical management of secondary
progressive multiple sclerosis (SPMS) because of the lack of definitive clinical, imaging …

Aging is a significant risk factor associated with the progression of CNS neurodegenerative
diseases including multiple sclerosis (MS). Microglia, the resident macrophages of the CNS …

Microglia in multiple sclerosis – pathogenesis and imaging : Current Opinion in Neurology
Microglia in multiple sclerosis – pathogenesis and imaging : Current Opinion in Neurology Log …